KITE 718

Drug Profile

KITE 718

Alternative Names: KITE-718

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kite Pharma
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunomodulators; MAGEA-3-protein-modulators; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 17 Aug 2017 Interim efficacy data from a phase I trial in Solid tumours (Late stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) released by Kite Pharma
  • 08 May 2017 Phase I clinical trials in Solid tumours (Late stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) in USA (IV) (Kite Pharma pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top